Search

Your search keyword '"Colorado Araujo, Mercedes"' showing total 10 results
Start Over Author "Colorado Araujo, Mercedes" Publication Year Range Last 50 years
10 results on '"Colorado Araujo, Mercedes"'

1. Feasibility of allogeneic hematopoietic stem cell transplantation in advanced age

Author

Fernandez-Luis, Sara, Gomez Lamas, David, Cerezo Martin, Juan Manuel, Mora Barrios, Juan Manuel, Yañez San Segundo, Lucrecia, Sanchez Escamilla, Miriam, Fernandez-Escalada, Noemi, Calvo Sanchez, Jose Alvaro, Fernandez Garcia, Sergio, Dominguez-Garcia, Juan Jose, Colorado Araujo, Mercedes, Lopez-Duarte, Monica, Martin-Sanchez, Guillermo, Insunza Gaminde, Andres, Romon Alonso, Jose Iñigo, Lobeira Rubio, Rocio, Arroyo Rodriguez, Jose Luis, Rueda Ciller, Beatriz, Hermosilla Fernandez, Mar, Marco Betes, Victor, Ocio, Enrique Maria, and Bermudez Rodriguez, Arancha

Published
2024
Full Text
View/download PDF

2. Autologous hematopoietic cell transplantation for relapsed multiple myeloma performed with cells procured after previous transplantation–study on behalf of CMWP of the EBMT

Author

Drozd-Sokołowska, Joanna, Gras, Luuk, Zinger, Nienke, Snowden, John A., Arat, Mutlu, Basak, Grzegorz, Pouli, Anastasia, Crawley, Charles, Wilson, Keith M. O., Tilly, Herve, Byrne, Jennifer, Bulabois, Claude Eric, Passweg, Jakob, Ozkurt, Zubeyde Nur, Schroyens, Wilfried, Lioure, Bruno, Colorado Araujo, Mercedes, Poiré, Xavier, Van Gorkom, Gwendolyn, Gurman, Gunhan, de Wreede, Liesbeth C., Hayden, Patrick J., Beksac, Meral, Schönland, Stefan O., and Yakoub-Agha, Ibrahim

Published
2022
Full Text
View/download PDF

3. Performance of prognostic scoring systems in elderly patients with acute myeloid leukaemia on intensive chemotherapy: A PETHEMA registry study

Author

Rodríguez-Medina, Carlos, Martínez-Cuadrón, David, Cano, Isabel, Gil, Cristina, Tormo, Mar, del Pilar Martínez-Sánchez, María, del Castillo, Teresa Bernal, Serrano-López, Josefina, Benavente, Celina, Herrera-Puente, Pilar, García-Boyero, Raimundo, Lavilla-Rubira, Esperanza, Amigo, Mª Luz, Sayas-Lloris, MªJose, Bergua-Burgues, Juan M, Pérez-Simón, José Antonio, Rodríguez, Gabriela, Espadana, Ana, Vidriales-Vicente, Belén, Fernández, Rosa, López-Lorenzo, Jose Luis, López, María, García-Fortes, María, Labrador Gómez, Jorge, Colorado-Araujo, Mercedes, Sossa-Melo, Claudia Lucia, Aguilar, Eliana, and Montesinos Fernández, Pau

Published
2020
Full Text
View/download PDF

4. Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice

Author

Garcia-Gutiérrez, Valentín, Luna, Alejandro, Alonso-Dominguez, Juan M., Estrada, Natalia, Boque, Concepcion, Xicoy, Blanca, Giraldo, Pilar, Angona, Anna, Alvarez-Larrán, Alberto, Sanchez-Guijo, Fermin, Ramírez, María José, Mora, Elvira, Vélez, Patricia, Rosell, Ana, Colorado Araujo, Mercedes, Cuevas, Beatriz, Sagüés, Miguel, Cortes, Montserrat, Encinas, Manuel Perez, Casado Montero, Luis Felipe, Moreno Vega, Melania, Serrano, Luis, Gomez, Valle, Garcia-Hernandez, Carmen, Lakhwani, Sunil, Paz Coll, Antonio, de Paz, Raquel, Suarez-Varela, Sara, Fernandez-Ruiz, Andrés, Perez Lopez, Raul, Ortiz-Fernández, Almudena, Jiménez-Velasco, Antonio, Steegmann-Olmedillas, Juan Luis, and Hernández-Boluda, Juan Carlos

Published
2021
Full Text
View/download PDF

5. Long-Term Outcomes After Autologous Versus Allogeneic Stem Cell Transplantation in Molecularly-Stratified Patients With Intermediate Cytogenetic Risk Acute Myeloid Leukemia: A PETHEMA Study

Author

Rodríguez-Arbolí, Eduardo, Martínez-Cuadrón, David, Rodríguez-Veiga, Rebeca, Carrillo-Cruz, Estrella, Gil-Cortés, Cristina, Serrano-López, Josefina, Bernal del Castillo, Teresa, Martínez-Sánchez, María del Pilar, Rodríguez-Medina, Carlos, Vidriales, Belén, Bergua, Juan Miguel, Benavente, Celina, García-Boyero, Raimundo, Herrera-Puente, Pilar, Algarra, Lorenzo, Sayas-Lloris, María José, Fernández, Rosa, Labrador, Jorge, Lavilla-Rubira, Esperanza, Barrios-García, Manuel, Tormo, Mar, Serrano-Maestro, Alfons, Sossa-Melo, Claudia Lucía, García-Belmonte, Daniel, Vives, Susana, Rodríguez-Gutiérrez, Juan Ignacio, Albo-López, Carmen, Garrastazul-Sánchez, María Paz, Colorado-Araujo, Mercedes, Mariz, José, Sanz, Miguel Ángel, Pérez-Simón, José Antonio, and Montesinos, Pau

Published
2021
Full Text
View/download PDF

6. Autologous hematopoietic cell transplantation for relapsed multiple myeloma performed with cells procured after previous transplantation–study on behalf of CMWP of the EBMT

Author

UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (SLuc) Centre du cancer, UCL - (SLuc) Service d'hématologie, Drozd-Sokołowska, Joanna, Gras, Luuk, Zinger, Nienke, Snowden, John A., Arat, Mutlu, Basak, Grzegorz, Pouli, Anastasia, Crawley, Charles, Wilson, Keith M. O., Tilly, Herve, Byrne, Jennifer, Bulabois, Claude Eric, Passweg, Jakob, Ozkurt, Zubeyde Nur, Schroyens, Wilfried, Lioure, Bruno, Colorado Araujo, Mercedes, Poiré, Xavier, Van Gorkom, Gwendolyn, Gurman, Gunhan, de Wreede, Liesbeth C., Hayden, Patrick J., Beksac, Meral, Schönland, Stefan O., Yakoub-Agha, Ibrahim, UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (SLuc) Centre du cancer, UCL - (SLuc) Service d'hématologie, Drozd-Sokołowska, Joanna, Gras, Luuk, Zinger, Nienke, Snowden, John A., Arat, Mutlu, Basak, Grzegorz, Pouli, Anastasia, Crawley, Charles, Wilson, Keith M. O., Tilly, Herve, Byrne, Jennifer, Bulabois, Claude Eric, Passweg, Jakob, Ozkurt, Zubeyde Nur, Schroyens, Wilfried, Lioure, Bruno, Colorado Araujo, Mercedes, Poiré, Xavier, Van Gorkom, Gwendolyn, Gurman, Gunhan, de Wreede, Liesbeth C., Hayden, Patrick J., Beksac, Meral, Schönland, Stefan O., and Yakoub-Agha, Ibrahim

Abstract

Autologous hematopoietic cell transplantation (auto-HCT) may be performed in multiple myeloma (MM) patients relapsing after a previous auto-HCT. For those without an adequate dose of stored stem cells, remobilization is necessary. This retrospective study included patients who, following disease relapse after the first auto-HCT(s), underwent stem cell remobilization and auto-HCT performed using these cells. There were 305 patients, 68% male, median age at salvage auto-HCT was 59 years. The median time to relapse after the first-line penultimate auto-HCT(s) was 30.6 months, the median follow-up after salvage auto-HCT 31 months. The 2- and 4-year non-relapse mortality (NRM) after the salvage auto-HCT was 5 and 9%, the relapse incidence 56 and 76%, respectively. Overall survival (OS) after 2 and 4 years was 76 and 52%, progression-free survival (PFS) 39 and 15%. In multivariable analysis an increasing interval between the penultimate auto-HCT and relapse was associated with better OS and PFS, later calendar year of salvage auto-HCT with better OS. In conclusion, salvage auto-HCT performed with cells remobilized after a previous auto-HCT was associated with acceptable NRM. The leading cause of failure was disease progression of MM, which correlated with a shorter interval from the penultimate auto-HCT to the first relapse.

Published
2022

7. Autologous Hematopoietic Cell Transplantation For Relapsed Multiple Myeloma Performed With Stem Cells Re-Mobilised Following A Prior AUTO-HCT - A Retrospective Study on Behalf of EBMT CMWP

Author

Byrne, Jennifer, Snowden, John A., Crawley, Charles, Colorado Araujo, Mercedes, de Wreede, Liesbeth, Passweg, Jakob, Van Gorkom, Gwendolyn, GÜRMAN, GÜNHAN, Zinger, Nienke, Gras, Luuk, Yakoub-Agha, Ibrahim, Schoenland, Stefan, Tilly, Herve, BEKSAÇ, MERAL, Hayden, Patrick, Bulabois, Claude Eric, Arat, Mutlu, Basak, Grzegorz, Pouli, Anastasia, Poire, Xavier, Wilson, Keith M. O., Lioure, Bruno, Schroyens, Wilfried, ÖZKURT, ZÜBEYDE NUR, and Drozd-Sokolowska, Joanna

Published
2021

8. Corrigendum to “Performance of prognostic scoring systems in elderly patients with acute myeloid leukaemia on intensive chemotherapy: A PETHEMA registry study” [Leuk. Res. 92 (March) (2020) 106352]

Author

Rodríguez-Medina, Carlos, Martínez-Cuadrón, David, Cano, Isabel, Gil, Cristina, Tormo, Mar, del Pilar Martínez-Sánchez, María, del Castillo, Teresa Bernal, Serrano-López, Josefina, Benavente, Celina, Herrera-Puente, Pilar, García-Boyero, Raimundo, Lavilla-Rubira, Esperanza, Luz Amigo, Mª, Sayas-Lloris, MªJose, Bergua-Burgues, Juan M., Pérez-Simón, José Antonio, Rodríguez, Gabriela, Espadana, Ana, Vidriales-Vicente, Belén, Fernández, Rosa, López-Lorenzo, Jose Luis, López, María, García-Fortes, María, Gómez, Jorge Labrador, Colorado-Araujo, Mercedes, Sossa-Melo, Claudia Lucia, Aguilar, Eliana, and Montesinos, Pau

Published
2020
Full Text
View/download PDF

9. Long-Term Outcomes After Autologous Versus Allogeneic Stem Cell Transplantation in Molecularly-Stratified Patients With Intermediate Cytogenetic Risk Acute Myeloid Leukemia: A PETHEMA Study

Author

Rodríguez-Arbolí, Eduardo, Martínez-Cuadrón, David, Rodríguez-Veiga, Rebeca, Carrillo-Cruz, Estrella, Gil-Cortés, Cristina, Serrano-López, Josefina, Bernal Del Castillo, Teresa, Martínez-Sánchez, María Del Pilar, Rodríguez-Medina, Carlos, Vidriales, Belén, Bergua, Juan Miguel, Benavente, Celina, García-Boyero, Raimundo, Herrera-Puente, Pilar, Algarra, Lorenzo, Sayas-Lloris, María José, Fernández, Rosa, Labrador, Jorge, Lavilla-Rubira, Esperanza, Barrios-García, Manuel, Tormo, Mar, Serrano-Maestro, Alfons, Sossa-Melo, Claudia Lucía, García-Belmonte, Daniel, Vives, Susana, Rodríguez-Gutiérrez, Juan Ignacio, Albo-López, Carmen, Garrastazul-Sánchez, María Paz, Colorado-Araujo, Mercedes, Mariz, José, Sanz, Miguel Ángel, Pérez-Simón, José Antonio, Montesinos, Pau, PETHEMA (Programa Español de Tratamientos en Hematología) and GETH (Grupo Español de Trasplante Hematopoyético y Terapia Celular) Cooperative Groups, Instituto de Salud Carlos III, and Centro de Investigación Biomédica en Red Cáncer (España)

Subjects
Oncology, medicine.medical_specialty, NPM1, European LeukemiaNet, Internal medicine, CEBPA, Immunology and Allergy, Medicine, Humans, Transplantation, Homologous, Cumulative incidence, Transplantation, Acute myeloid leukemia, business.industry, Remission Induction, Hematopoietic Stem Cell Transplantation, Myeloid leukemia, Cell Biology, Hematology, Confidence interval, Allogeneic stem cell transplant, Leukemia, Myeloid, Acute, Autologous stem cell transplant, Cytogenetic Analysis, Molecular Medicine, Stem cell, business, Nucleophosmin
Abstract

PETHEMA (Programa Español de Tratamientos en Hematología) and GETH (Grupo Espa~nol de Trasplante Hematopoyético y Terapia Celular) Cooperative Groups, Acute myeloid leukemia (AML) with intermediate risk cytogenetics (IRcyto) comprises a variety of biological entities with distinct mutational landscapes that translate into differential risks of relapse and prognosis. Optimal postremission therapy choice in this heterogeneous patient population is currently unsettled. In the current study, we compared outcomes in IRcyto AML recipients of autologous (autoSCT) (n = 312) or allogeneic stem cell transplantation (alloSCT) (n = 279) in first complete remission (CR1). Molecular risk was defined based on CEBPA, NPM1, and FLT3-ITD mutational status, per European LeukemiaNet 2017 criteria. Five-year overall survival (OS) in patients with favorable molecular risk (FRmol) was 62% (95% confidence interval [CI], 50-72) after autoSCT and 66% (95% CI, 41-83) after matched sibling donor (MSD) alloSCT (P = .68). For patients of intermediate molecular risk (IRmol), MSD alloSCT was associated with lower cumulative incidence of relapse (P < .001), as well as with increased nonrelapse mortality (P = .01), as compared to autoSCT. The 5-year OS was 47% (95% CI, 34-58) after autoSCT and 70% (95% CI, 59-79) after MSD alloSCT (P = .02) in this patient subgroup. In a propensity-score matched IRmol subcohort (n = 106), MSD alloSCT was associated with superior leukemia-free survival (hazard ratio [HR] 0.33, P = .004) and increased OS in patients alive 1 year after transplantation (HR 0.20, P = .004). These results indicate that, within IRcyto AML in CR1, autoSCT may be a valid option for FRmol patients, whereas MSD alloSCT should be the preferred postremission strategy in IRmol patients., Supported by a Río Hortega academic clinical fellowship (CM19/00194) from the Instituto de Salud Carlos III, Spain (E.R.A.). Additional funding has been provided by CIBERONC grants to J.P.S. (CB16/12/00480), M.M.S. (CB16/12/00369) and B.V. (CB16/12/00233).

Published
2020

10. Long-Term Outcomes After Autologous Versus Allogeneic Stem Cell Transplantation in Molecularly-Stratified Patients With Intermediate Cytogenetic Risk Acute Myeloid Leukemia: A PETHEMA Study

Author

Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red Cáncer (España), Rodríguez-Arbolí, Eduardo, Martínez-Cuadrón, David, Rodríguez-Veiga, Rebeca, Carrillo Cruz, Estrella, Gil-Cortés, Cristina, Serrano-López, Josefina, Bernal del Castillo, Teresa, Martínez-Sánchez, María Pilar, Rodríguez-Medina, Carlos, Vidriales, Maria Belén, Bergua, Juan, Benavente, Celina, García-Boyero, Raimundo, Herrera-Puente, Pilar, Algarra, Lorenzo, Sayas, María-José, Fernández, Rosa, Labrador, Jorge, Lavilla, Esperanza, Barrios-García, Manuel, Tormo, Mar, Serrano-Maestro, Alfons, Sossa-Melo, Claudia Lucía, García-Belmonte, Daniel, Vives, Susana, Rodríguez-Gutiérrez, Juan I., Albo-López, Carmen, Garrastazul-Sánchez, María Paz, Colorado-Araujo, Mercedes, Mariz, José, Sanz, Miguel Ángel, Pérez-Simón, José A., Montesinos, Pau, Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red Cáncer (España), Rodríguez-Arbolí, Eduardo, Martínez-Cuadrón, David, Rodríguez-Veiga, Rebeca, Carrillo Cruz, Estrella, Gil-Cortés, Cristina, Serrano-López, Josefina, Bernal del Castillo, Teresa, Martínez-Sánchez, María Pilar, Rodríguez-Medina, Carlos, Vidriales, Maria Belén, Bergua, Juan, Benavente, Celina, García-Boyero, Raimundo, Herrera-Puente, Pilar, Algarra, Lorenzo, Sayas, María-José, Fernández, Rosa, Labrador, Jorge, Lavilla, Esperanza, Barrios-García, Manuel, Tormo, Mar, Serrano-Maestro, Alfons, Sossa-Melo, Claudia Lucía, García-Belmonte, Daniel, Vives, Susana, Rodríguez-Gutiérrez, Juan I., Albo-López, Carmen, Garrastazul-Sánchez, María Paz, Colorado-Araujo, Mercedes, Mariz, José, Sanz, Miguel Ángel, Pérez-Simón, José A., and Montesinos, Pau

Abstract

Acute myeloid leukemia (AML) with intermediate risk cytogenetics (IRcyto) comprises a variety of biological entities with distinct mutational landscapes that translate into differential risks of relapse and prognosis. Optimal postremission therapy choice in this heterogeneous patient population is currently unsettled. In the current study, we compared outcomes in IRcyto AML recipients of autologous (autoSCT) (n = 312) or allogeneic stem cell transplantation (alloSCT) (n = 279) in first complete remission (CR1). Molecular risk was defined based on CEBPA, NPM1, and FLT3-ITD mutational status, per European LeukemiaNet 2017 criteria. Five-year overall survival (OS) in patients with favorable molecular risk (FRmol) was 62% (95% confidence interval [CI], 50-72) after autoSCT and 66% (95% CI, 41-83) after matched sibling donor (MSD) alloSCT (P = .68). For patients of intermediate molecular risk (IRmol), MSD alloSCT was associated with lower cumulative incidence of relapse (P < .001), as well as with increased nonrelapse mortality (P = .01), as compared to autoSCT. The 5-year OS was 47% (95% CI, 34-58) after autoSCT and 70% (95% CI, 59-79) after MSD alloSCT (P = .02) in this patient subgroup. In a propensity-score matched IRmol subcohort (n = 106), MSD alloSCT was associated with superior leukemia-free survival (hazard ratio [HR] 0.33, P = .004) and increased OS in patients alive 1 year after transplantation (HR 0.20, P = .004). These results indicate that, within IRcyto AML in CR1, autoSCT may be a valid option for FRmol patients, whereas MSD alloSCT should be the preferred postremission strategy in IRmol patients.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results